Plumbagin protects against glucocorticoid-induced osteoporosis through Nrf-2 pathway

Plumbagin Mediates Cardioprotection Against Myocardial Ischemia/Reperfusion Injury Through Nrf-2 Signaling

BACKGROUND Plumbagin is a potent antioxidant with anti-inflammatory and anti-carcinogenic action. Myocardial ischemia/reperfusion injury results in organ damage through oxidative stress and inflammatory mechanisms. In this study, we analyzed the potential role of plumbagin against myocardial I/R injury in Wistar rats. MATERIAL AND METHODS Oxidative stress was measured through ROS, lipid peroxid...

Glucocorticoid-induced Osteoporosis

Glucocorticoid induced osteoporosis.

Glucocorticoid therapy is the most common cause of secondary osteoporosis and the leading iatrogenic cause of the disease. Often, the presenting manifestation is fracture, which occurs in 30% to 50% of patients receiving long-term glucocorticoid therapy. Glucocorticoid-induced osteoporosis predominantly affects regions of the skeleton that have abundant cancellous bone such as lumbar spine and ...

Glucocorticoid-induced osteoporosis

Corticosteroid-induced osteoporosis is the most common form of secondary osteoporosis and the first cause in young people. Bone loss and increased rate of fractures occur early after the initiation of corticosteroid therapy, and are then related to dosage and treatment duration. The increase in fracture risk is not fully assessed by bone mineral density measurements, as it is also related to al...

Glucocorticoid-induced osteoporosis.

Glucocorticoid-induced osteoporosis is one of the most important side-effects of glucocorticoid use, leading to an increased fracture risk. In this review, recent advances in the understanding of the mechanisms of glucocorticoid-induced osteoporosis are summarised. Methods to identify persons at risk for fractures are discussed, as well as the new ACR recommendations for the prevention and trea...